Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Effective tax rate (%)

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEffective tax rate (%) (Million JPY)YoY (%)
Mar 31, 2025-125.5-2082.99%
Mar 31, 20246.3-559.08%
Mar 31, 2023-1.4+414.04%
Mar 31, 2022-0.3+25.93%
Mar 31, 2021-0.2-10.61%
Mar 31, 2020-0.2+5.75%
Mar 31, 2019-0.2-101.92%
Mar 31, 201811.7+397.38%
Mar 31, 20172.4+52.28%
Mar 31, 20161.5+37.81%
Mar 31, 20151.1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)